Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07492641 · ClinicalTrials.gov registry record · Phase 3
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
A Phase 3 study, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,056
- Enrollment target
NCT07492641 is a Phase 3 study that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 1,056 participants.
The verdict
NCT07492641, a Phase 3 study, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,056 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.
Interventions
- DRUG Letrozole
- DRUG Palbociclib
- DRUG Abemaciclib
- DRUG Ribociclib
- DRUG BGB-43395
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2037-08-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07492641
The ClinicalTrials.gov registry entry for NCT07492641 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Letrozole is the first listed.
NCT07492641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07492641 about?
NCT07492641 is a clinical study titled "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease". The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/...
What is the current status of trial NCT07492641?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,056 participants. The study started on 2026-05-22. Estimated completion is 2037-08-07.
What interventions are being tested in trial NCT07492641?
The interventions under investigation include: Letrozole (DRUG), Palbociclib (DRUG), Abemaciclib (DRUG), Ribociclib (DRUG), BGB-43395 (DRUG).
Who is sponsoring clinical trial NCT07492641?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.